Spooling Along: Ariad, Merck Get SPA For Phase III Trial Of Oral Deforolimus
This article was originally published in The Pink Sheet Daily
Executive Summary
Ariad seeking indication in metastatic soft tissue and bone sarcomas, with progression-free survival primary endpoint.
You may also be interested in...
Merck/Ariad Form Billion-Dollar Collaboration To Develop mTOR Inhibitor For Cancers
Merck’s commitment to using biomarkers, bioinformatics and diagnostics in cancer drug development was key to the deal, Ariad CEO tells “The Pink Sheet” DAILY.
Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee